CTRI/2023/05/052666尚未招募Unknown
A Study of Individualized Molecular Profiling Guided Therapy Based on Deciphering Recondite Molecular Alterations and Variations in Advanced Solid Tumors - I-DRAV study
Dr. AV Cancer Institute of Personalized Cancer Treatment and Research0 个研究点目标入组 0 人开始时间: 待定最近更新:
试验速览
- 阶段
- Unknown
- 状态
- 尚未招募
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
入选标准
- •Male and female patients >= 18 years of age, who have agreed to receive either molecularly targeted matched treatment based on molecular profiling analysis or conventional anti-cancer treatment in routine clinical practice as per their discussion with the treating physician and have provided written informed consent for participation in the study.
- •Patients with incurable malignancies.
- •Patients with cancer of unknown primary, or a rare tumor with no approved therapies.
- •Patients with cancers of hereditary in nature
- •Patients must have the following for a diagnosis/disease status: Relapsed or refractory advanced/metastatic disease, Actionable alterations determined by molecular profiling
- •Molecular profiling (including one or more technologies but not limited to NGS, FISH, IHC, PCR, Microarray, and histopathology) for tumor and/ or blood analysis results should be available with all patients.
- •Known disease status post one or more unmatched systemic therapy regimens.
- •Patients must have a measurable disease for malignancies: defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded for non-nodal lesions and short axis for nodal lesions) as >=20 mm with conventional techniques or as >=10 mm with spiral CT scan, PET-CT, MRI, or calipers by clinical exam or liquid biopsy showing the ctDNA fraction.
- •ECOG Performance Status 0-2.
- •New York Heart Association (NYHA) Functional Classification I-II.
- •Adequate organ and marrow function
- •At the time of treatment, patients should be off other anti-tumor agents for at least 5 half-lives of the agent or 3 weeks from the last day of treatment, whichever is shorter. Patients must be off prior antibody therapy for at least 3 half-lives before starting treatment.
- •Able to swallow and retain oral medication if needed.
- •Female patients of childbearing potential must have a negative serum/ urine pregnancy test and agree to use at least one form of pregnancy prevention during the study and for at least one month after treatment discontinuation. For the purposes of this study, the child-bearing potential is defined as all female patients that were not in post-menopause for at least one year or are surgically sterile.
- •Male patients must use a form of barrier pregnancy prevention approved by the investigator/ treating physician during the study and for at least one month after treatment discontinuation.
排除标准
- •Severe or uncontrolled medical disorder
- •Pregnant or lactating women
研究者
相似试验
进行中（未招募）
不适用
Personalized Molecular Profiling in Cancer Treatment at Johns HopkinsMetastatic Breast CancerNCT02965755Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins200
招募中
不适用
Molecular Profile-related Individualized Targeted Therapy in Resected Pancreatic Cancer With High-Risk of Cancer RecurrencePancreas CancerNCT06228599Medical College of Wisconsin40
Unknown
不适用
Profile Related Evidence to Determine Individualized Cancer Therapy (PREDICT) Program in Advanced Cancer PatientsAdvanced CancersNCT02160366M.D. Anderson Cancer Center2,000
招募中
不适用
Individualized Molecular Profiling for Allocation to Clinical Trials (IMPACT) ProjectSolid TumorNCT02806388National Cancer Centre, Singapore5,500
终止
不适用
An Open Label Navigational Investigation of Molecular Profile-Related Evidence Determining Individualized Cancer Therapy for Patients With Incurable Hematologic Malignancies (I-PREDICT Heme)Hematologic CancerNCT03955276University of California, San Diego13